Advanced search
Publication Cover
Emerging Therapeutic Targets Volume 4, 2000 - Issue 6
Journal homepage
17
Views
1
CrossRef citations to date
0
Altmetric
Review

Treating systemic prostate cancer: emerging drug targets and therapies

James Gulley National Cancer Institute, Building 10, Room 8B08, 10 Center Drive, Bethesda, MD 20892, USA. [email protected]
,
Philip Arlen National Cancer Institute, Building 10, Room 8B08, 10 Center Drive, Bethesda, MD 20892, USA. [email protected]
&
William Dahut National Cancer Institute, Building 10, Room 13N226, 10 Center Drive, Bethesda, MD 20892, USA. [email protected]
Pages 751-763 | Published online: 25 Feb 2005

Bibliography

  • INOHARA N, DING L, CHEN S, NUNEZ G: Harakiri, anovel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bc1-2 and Bc1-X(L). EMBO J. (1997) 16(7):1686–1694.
  • SANZ C, BENITO A, INOHARA N, EKHTERAE D, NUNEZ G, FERNANDEZ-LUNA JL: Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood (2000) 95 (9):2742–2747.
  • UN J, PAGE C, INOHARA N, NUNEZ G, ZHAO S, DAY ML:Expression of pro-apoptotic genes as competitive inhibitors to Bc1-2 and Bc1-XLin prostate cancer cells. Proceedings of the American Association for Cancer Research. San Francisco, USA (2000). Abstract 263.
  • CHEEMA S, TARI AM, RANGNEKAR VM, BERNSTEIN GL:Growth regulation of prostate cancer cell lines by Bc1-2 down modulation. Proceedings of the American Associa-tion for Cancer Research. San Francisco, USA (2000). Abstract 264.
  • TRUMP DL, SMITH DC, STIFF D et al.: A Phase II trial ofall-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemother. Pharmacol. (1997) 39(0349–356.
  • KELLY WK, SCHER HI, MUINDI J et al.: Phase II ofall-trans retinoic acid in patients with adenocarci-noma. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1993) 34:1210.
  • HIGGIN B, DROBNJAK M, CORDON-CARDO C, AGUS DB:Anti-tumor activity of Apo2 ligand (TRAIL) in androgen-dependent and androgen-in dep en dent human prostate cancer xenograft models. Proceedings of the American Association for Cancer Research, San Francisco, USA (2000). Abstract 265.
  • FURUYA Y, LUNDMO P, SHORT AD, GILL DL, ISAACS JT:The role of calcium, pH and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsi-gargin. Cancer Res. (1994) 54(23):6167–6175.
  • BROGGER S., ANDERSEN A, KROMANN H, TREIMAN M, TOMBAL B, DENMEADE S, ISAACS JT: Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg. Med. Chem. (1999) 7:1273–1280.
  • •Reports a novel compound activated by PSA and therefore targeted to prostate cells.
  • GLEAVE ME, MIAYAKE H, GOLDIE J, NELSON C, TOLCHER A: Targeting bc1-2 gene to delay androgen-independent progression and enhance chemosensi-tivity in prostate cancer using antisense bc1-2 oligode-oxynucleotides. Urology (1999) 54 (Suppl.):36–46.
  • •Interesting gene therapy approach.
  • CHI KN, GLEAVE ME, KLASA R, MURRAY N, BRYCE C, TOLCHER A: A Phase I Trial of an Antisense Oligonu-cleotide to BCL-2 (G3139, Genta) and Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer (HRPC). American Society of Clinical Oncology 36th Annual Meeting. New Orleans, USA (2000). Abstract 1299.
  • EDER IE, RAMONER R, CULIG Z, BARTSCH G, KLOCKER H:Induction of apoptosis by downregulation of androgen receptor with antisense oligodeoxynucleo-tides. American Urological Association. Atlanta, USA (2000). Abstract 430.
  • GOLUBOFF ET, SHABIGH A, SAIDI JA et al.: Exisulind(sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology (1999) 53 (2):440–445.
  • LIM JTE, PIAZZA GA, HAN EK et al.: Sulindac derivativesinhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. (1999) 58:1097–1107.
  • GOLUBOFF E, OLSSON C, PRAGER D et al.: Exisulindinhibits the progression of prostate cancer in men following radical prostatectomy. American Urological Association. Atlanta, USA (2000). Abstract 705.
  • •Phase I/II trial showing safety and efficacy of exisulind in patients with biochemical failure following local therapy.
  • WULLICH B, RHODE V, OEHLENSCHLAGER B et al.: Focal intratumoral heterogeneity for telomerase activity in human prostate cancer. J. Urol. (1999) 161 (6):1997–2001.
  • KONDO Y, KOGA S, KOMATA T, KONDO S: Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene (2000) 19 (18): 2205–2211.
  • WEI C, STOROZYNSKY E, MCADAM AJ et al.: Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. (1996) 42:362–368.
  • CORREALE P, WALMSLEY K, ZAREMBA S, ZHU M, SCHLOM J, TSANG KY: Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol (1998) 161:3186–3194.
  • •Study showing that PSA can elicit a specific cytotoxic immune response.
  • MEIDENBAUER N, HARRIS DT, SPITLER LE, WHITESIDE TL: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate (2000) 43 (2):88–100.
  • EDER JP, KANTOFF PW, ROPER K et al.: APhase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6(5):1632–1638.
  • •Phase I trial showing immune response to PSA vaccine with promising clinical results.
  • FONG L, ENGLEMAN EG: Dendritic cells in cancer immunotherapy. Ann. Rev. Iminunol. (2000) 18:245–273.
  • •Review of the use of dendritic cells for cancer immunotherapy.
  • MURPHY GP, TJOA BA, SIMMONS SJ et al.: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 39 (1):54–59.
  • MURPHY GP, TJOA BA, SIMMONS SJ et al: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate (1999) 38 (1):73–78.
  • LODGE PA, JONES LA, BADER RA, MURPHY GP, SALGALLER ML: Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a Phase II clinical trial. Cancer Res. (2000) 6 0 (4):829–833.
  • HARRIS DT, MATYAS GR, GOMELLA LG et al: Immuno-logic approaches to the treatment of prostate cancer. Semin. Oncol. (1999) 2 6 (4)439–447.
  • •A review of prostate cancer immunotherapy.
  • SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59(205160–5168.
  • SMALL EJ, REESE DM, UM B, WHISENANT S, DIXON SC, FIGG WD: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. (1999) 5(7):1738–1744.
  • YAO D, RICHSTONE L, KIM S, LIU H, CHARI RVJ, BANDERNH: Use of a monoclonal antibody to the extra-cellular domain of prostate-specific membrane antigen (PSMA ext) for targeted deliver of cytotoxic drugs to prostate cancer cells. American Urological Association. Atlanta, USA (2000). Abstract 125.
  • BANDER N, NANUS D, BREMER S et al: Phase I clinicaltrial targeting a monoclonal antibody (mAb) to the extracellular domain of prostate specific membrane antigen (PSMAext) in hormone-independent patients. American Urological Association. Atlanta, USA (2000). Abstract 712.
  • AGUS DB, SCHER HI, HIGGINS B et al.: Response ofprostate cancer to anti-Her-2 /neu antibody in androgen-dependent and-independent human xenograft models. Cancer Res. (1999) 59(104761–4764.
  • MORRIS M, REUTER VE, KELLY WK et al.: A Phase II trialof hercep tin alone and with Taxol for the treatment of prostate cancer. American Society of Clinical Oncology 36th Annual Meeting New Orleans, USA (2000). Abstract 1298.
  • SAMID D, SHACK S, MYERS CE: Selective growth arrestand phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. j Clin. Invest. (1993) 91 (5):2288–2295.
  • THIBAULT A, COOPER MR, FIGG WD et al.: APhase land pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. (1994) 54 (7):1690–1694.
  • THIBAULT A, SAMID D, COOPER MR et al.: Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (1995) 75 (12):2932–2938.
  • CARDUCCI MA, NELSON JB, CHAN-TACK KM et al.: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. (1996) 2(2):379–387.
  • NG AY, BALES W, VELTRI RW: Phenylbutyrate-inducedapoptosis and differential expression of Bc1-2, Bax, p53 and Fas in human prostate cancer cell lines. Anal. Quant. Cytol. Histol (2000) 22 (1):45–54.
  • CARDUCCI M, BOWLING M, EISENBERGER M et al.: Oralsodium phenylbutyrate (PB) for refractory solid tumors: Phase I and bioavailability assessment. American Society of Clinical Oncology 34th Annual Meeting. Los Angeles, USA (1998). Abstract 831.
  • UMBAS R, ISAACS WB, BRINGUIER PP et al.: DecreasedE-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. (1994) 54(14):3929–3933.
  • TOMITA K, VAN BOKHOVEN A, VAN LEENDERS GJ et al.: Cadherin switching in human prostate cancer progression. Cancer Res. (2000) 6 0 (13):3650–3654.
  • LUO J, LUBAROFF DM, HENDRIX MJ: Suppression of prostate cancer invasive potential and matrix met allo-proteinase activity by E-cadherin transfection. Cancer Res. (1999) 59(15):3552–3556.
  • DJAKIEW D, DELSITE R, PFLUG B, WRATHALL J, LYNCHJH, ONODA M: Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res. (1991) 51 (12):3304–3310.
  • KIM HG, KASSIS J, SOUTO JC, TURNER T, WELLS A: EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol. Histopathol. (1999) 14(01175–1182.
  • PUTZ T, CULIG Z, EDER IE et al.: Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth Factor I and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res. (1999) 59 (1):227–233.
  • BASELGA J, HERBST R, LORUSSO P et al: Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. American Society of Clinical Oncology 36th Annual Meeting. New Orleans, USA (2000). Abstract 686.
  • •Phase I clinical trial of Iressa.
  • FERRY D, HAMMOND L, RANSON M et al.: Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a Phase I study. American Society of Clinical Oncology 36th Annual Meeting New Orleans, USA (2000). Abstract 5–E.
  • •Phase I clinical trial of Iressa.
  • PREWETT M, ROCKWELL P, ROCKWELL RF et al.: The biologic effects of C225, a chimeric monoclonal antibody to the EGER, on human prostate carcinoma./ Immunother. Emphasis Tumor Immunol. (1996) 19(6):419–427.
  • YE D, MENDELSOHN J, FAN Z: Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin. Cancer Res. (1999) 5(8):2171–2177.
  • GUNNETT K, MOTZER R, AMATO R et al.: Phase II Study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC). American Society of Clinical Oncology 35th Annual Meeting. Atlanta, USA (1999). Abstract 1309.
  • BONNER JA, EZEKIEL MP, ROBERT F, MEREDITH RF, SPENCER SA, WAKSAL HW: Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies. American Society of Clinical Oncology 36th Annual Meeting New Orleans, USA (2000). Abstract 5–F.
  • DJAKIEW D, PFLUG BR, DELSITE R et al.: Chemotaxis andchemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res. (1993) 53(6):1416–1420.
  • GELDOF AA, DE KLEIJN MA, RAO BR, NEWLING DW: Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells. J. Cancer Res. Clin. Oncol (1997) 123(2):107–112.
  • PLONOWSKI A, SCHALLY AV, VARGA JL et al.: Potentia-tion of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate (2000) 44 (2) :172–180.
  • GEORGE DJ, DIONNE CA, JANI J et al.: Sustained in vivoregression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. (1999) 59(102395–2401.
  • MARSHALL J, BHARGAVA P, KINDLER H et al.: Phase I study of oral CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. American Society of Clinical Oncology 36th Annual Meeting New Orleans, USA (2000). Abstract 713.
  • FOLKMAN J: Tumor angiogenesis: therapeutic implica-tions. N Engl. J. Med. (1971) 285:1182–1186.
  • •Historic article proposing therapeutic modalities to block tumour angiogenesis.
  • WEIDNER N, CARROLL PR, FLAX J, BLUMENFELD W, FOLKMAN J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. (1993) 143:401–409.
  • D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Nati Acad. Sci. USA (1994) 91:4082–4085.
  • GUINAN P, SHAW M, MIROCHNIK Y, SLOBODSKOY L, RAY V, RUBENSTEIN M: Paclitax el is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model. Methods Find. Exp. Clin. Pharmacol. (1998) 20 (9) :739–742.
  • KLEINER DE, STETLER-STEVENSON WG: Structural biochemistry and activation of matrix met alloprote-inases. Curr. Opin. Cell. Biol. (1993) 5:891–897.
  • GOMEZ DE, ALONSO DF, YOSHIJI H, THORGEIRSSON UP: Tissue inhibitors of met allo-proteinases-structure, regulation and biological functions. Eur. J. Cell. Biol. (1997) 74:111–122.
  • •Review of matrix met alloproteinases.
  • BECKET RP, DAVIDSON AH, DRUMMOND AH, HUXLEY P, WHITTAKER M: Recent advances in matrix met allopro-teinase inhibitor research. Drug Dev. Today (1996) 1:16–26.
  • RASMUSSEN HK, MCCANN PP: Matrix met alloproteinaseinhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. (1997) 75:69–75.
  • STEARNS ME, WANG M: Tax ol block processes essential for prostate tumor cell (PC-3ML) invasion and metastases. Cancer Res. (1992) 52: 3776–3781.
  • STEARNS ME, WANG M: Effects of alendronate and Taxol on PCML cell bone metastases in SCID mice. Invasion Metast. (1996) 16:116–131.
  • BOISSIER S, FERRERAS M, PEYRUCHAUD O et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. (2000) 60:2949–2954.
  • DAHUT W, DYER V, ARLEN P et al.: A randomized PhaseII trial of ketoconazole (KT) and alendronate (AL) versus high dose ketoconazole in androgen independent metastatic prostate cancer wpg. AUA 95th Annual Meeting. Atlanta, USA (2000). Abstract 1165.
  • HANRAHAN CF, DE MARZO AM, ZHONG H et al.: Overproduction of hypoxia-inducible factor 1 in high-grade prostatic intraepithelial neoplasia. Proceedings of the American Association for Cancer Research. San Francisco, USA (2000). Abstract 252.
  • MCMENAMIN ME, SOUNG P, PERERA S, KAPLAN I, LODA M, SELLERS WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. (1999) 59(17):4291–4296.
  • ZHONG H, CHILES K, FELDSER D et al: Modulation of hypoxia-inducible factor lalpha expression by the epidermal growth factor /phosphatidylinositol 3-kin ase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. (2000) 60 (6) : 1541–1545.
  • HERMAN JR, ADLER HL, AGUILAR-CORDOVA E et al: In sitilgene therapy for adenocarcinoma of the prostate: a Phase I clinical trial. Hum. Gene Ther. (1999) 10 (7) :1239–1249.

Websites

  • http://www.cancer.org/ American Cancer Society homepage (Nov 2000).
  • http://www.cellpathways.com/ Cell Pathways, Inc. homepage (Nov 2000).
  • http://www.therionbio.com/ Therion Biologics Corp. homepage (Nov 2000).
  • http://www.cel-sci.com/index.shtml Cel-Sci, Inc. homepage (Nov 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.